(Q28200449)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

review article

1 reference

title

Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Stefania Momi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular Drug Reviews

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

148-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16961726%20AND%20SRC:MED&resulttype=core&format=json

The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Molecular targets of nitric-oxide-donating aspirin in cancer

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Low-dose aspirin for the prevention of atherothrombosis

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Mandate to modify a medicinal mantra: maybe not yet?

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Vascular protective actions of a nitric oxide aspirin analog in both in vitro and in vivo models of diabetes mellitus

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Nitric oxide-releasing aspirin inhibits vasoconstriction in perfused tail artery of normotensive and spontaneously hypertensive rats

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Inflammation and insulin resistance

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Nitric oxide-modulating agents for gastrointestinal disorders

20 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1527-3466.2006.00148.X

Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin

20 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric-oxide releasing molecules: a new class of drugs with several major indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

NO-aspirins: a class of new anti-inflammatory and antithrombotic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric oxide and its relationship to thrombotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Platelets in inflammation and atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Novel approaches to the treatment of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Antithrombotic drugs: insights from cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

COX-inhibiting nitric oxide donors (CINODs): potential benefits on cardiovascular and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric oxide and its antithrombotic action in the cardiovascular system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric-oxide-donating NSAIDs as agents for cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

The therapeutic potential of NO-NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric oxide in mucosal defense: a little goes a long way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X

Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2006.00148.X